Surgical Options – Ablative Techniques
Chapter 3Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the preferred surgical options for patients with kidney cancer.
Targeted Therapy in Locally Advanced RCC
Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss treatment options and ongoing research related to locally advanced renal cell carcinoma (RCC).
The Role of Neoadjuvant Therapy
Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the role of neoadjuvant therapy in the treatment of patients with renal cell carcinoma (RCC).
Surgical Options – Lymph Node
Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the standards for decision making related to lymph node dissection in patients with renal cell carcinoma (RCC).
Surgical Options – Cytoreductive Nephrectomy
Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the paradigm of cytoreductive nephrectomy and its role in the management of metastatic renal cell carcinoma (RCC).
Tyrosine Kinase Inhibitors - First-Line Therapy
Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the use of tyrosine kinase inhibitors in patients with advanced renal cell carcinoma and how they differ from other targeted therapies.
Tyrosine Kinanse Inhibitors – Second-Line Therapy
Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss the use of tyrosine kinase inhibitors in the refractory renal cell carcinoma (RCC).
Biomarkers in Renal Cell Carcinoma
Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss biomarkers and how they relate to the treatment of advanced renal cell carcinoma (RCC).
The MET Pathway
Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, discuss a newer potential target in RCC—MET.
Checkpoint Inhibitors
Brian Rini, MD, Steven Campbell, MD, PhD, David McDermott, MD, and Robert Motzer, MD, review the role of checkpoint inhibitors in the treatment of patients with kidney cancer.
